Devimistat

Devimistat plus a modified standard-of-care chemotherapy regimen failed to extend OS among patients with metastatic pancreatic cancer, according to results of the randomized phase 3 AVENGER 500 trial released by the agent’s manufacturer.

The FDA granted priority review designation and fast track status to several agents under investigation for the treatment of various solid tumors and hematologic malignancies.

The FDA granted fast track designation to devimistat for treatment of acute myeloid leukemia, according to the agent’s manufacturer.

The FDA granted fast track designation to devimistat for the treatment of pancreatic cancer, according to the agent’s manufacturer.

Researchers at Stony Brook University’s Renaissance School of Medicine have developed an enzyme-targeting drug that could prolong survival for patients with metastatic pancreatic cancer.